TRINETRA › Sectors › Healthcare
Ajanta Pharma Limited (AJANTPHARM) — share price, P/E and fundamentals
Ajanta Pharma Limited (NSE: AJANTPHARM) closed at ₹3,508.80 on 30 Oct 2026, +43.9% over one year, against a 52-week range of ₹2,382.00 – ₹3,796.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹1,794 cr and net profit of ₹388 cr, a 21.6% net margin; revenue grew 32.5% and profit grew 57.0% year on year.
On four consecutive filed quarters its trailing P/E is 34.8; since 30 Apr 2025 its own P/E has ranged from 32.5 to 42.3 (median 36.0), and today's reading is higher than 24% of those 371 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 32.0%, ROCE 42.3%, debt-to-equity 0.02, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 79% of 63 sector peers; PBT margin higher than 82% of 63 sector peers; ROE higher than 97% of 63 sector peers.
Key figures
| Last close | ₹3,508.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -0.9% / +26.9% / +43.9% |
| 52-week low – high | ₹2,382.00 – ₹3,796.00 |
| Market capitalisation | ₹43,983 cr |
| Trailing P/E | 34.8 |
| Price / book | 9.05 |
| EV / EBITDA | 23.4 |
| Earnings yield | 2.9% |
| TTM EPS | ₹100.74 |
| TTM net profit | ₹1,263 cr |
| Quarter revenue | ₹1,794 cr |
| Quarter net profit | ₹388 cr |
| Net margin | 21.6% |
| Revenue growth (YoY) | +32.5% |
| Profit growth (YoY) | +57.0% |
| Return on equity | 32.0% |
| ROCE | 42.3% |
| Debt / equity | 0.02 |
| Current ratio | 2.85 |
| Free cash flow | ₹490 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹28.0 cr |
Against Healthcare peers
| Metric | AJANTPHARM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 21.63 | 12.67 | 79 |
| PBT margin | 29.83 | 17.57 | 83 |
| ROE | 31.96 | 13.86 | 97 |
| ROCE | 42.29 | 16.59 | 97 |
| Debt / equity | 0.02 | 0.11 | 35 |
| FCF margin | 14.34 | -0.87 | 67 |
| Cash conversion | 1.04 | 1.25 | 36 |
| Trailing P/E | 34.83 | 43.26 | 29 |
Questions
What is the P/E ratio of Ajanta Pharma Limited?
Ajanta Pharma Limited's trailing P/E is 34.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 30 Apr 2025 its P/E has ranged 32.5–42.3.
What were Ajanta Pharma Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Ajanta Pharma Limited reported revenue of ₹1,794 cr and net profit of ₹388 cr (consolidated), filed with the exchange on 30 Oct 2026.
What is Ajanta Pharma Limited's ROE?
Return on equity is 32.0% based on the balance sheet dated 30 Sept 2026.
Does Ajanta Pharma Limited have debt?
Debt-to-equity is 0.02 on the balance sheet dated 30 Sept 2026.
What is AJANTPHARM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AJANTPHARM traded between ₹2,382.00 and ₹3,796.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.